LIMINATUS PHARMA, INC.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-1.4M | $-1.1M | $-8.2M | $-1.8M | $113.3K | $-327.5K | $-229.8K | $-601.4K |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $468 | $518 | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-970.0K | $-2.0M | $-386.8K | $-600.6K | $-8.8M | $-159.4K | $-140.7K | $-206.1K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | $0 | $-13.1K | $-200.0K | $-575.0K | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $2.1M | $3.6M | $0 | $0 | $10.3M | $713.0K | — | — |
| Net Change in Cash | $1.1M | $1.6M | $-386.8K | $-613.7K | $1.3M | $-21.4K | $9.3K | $12.9K |
| Free Cash Flow | — | — | — | — | — | — | — | — |